公开(公告)号：US20100029551A1

公开(公告)日：2010-02-04

申请号：US12533779

申请日：2009-07-31

申请人： Howard V. Raff ,  Ralph Niven

发明人： Howard V. Raff ,  Ralph Niven

IPC分类号： A61K31/7048 ,  A61P29/00 ,  A61K38/13

CPC分类号： A61K31/7048 ,  A61K9/008 ,  A61K38/13 ,  A61K2300/00

摘要： Provided herein are pharmaceutical compositions comprising an anti-inflammatory macrolide compound suitable for aerosolized administration to the lungs by inhalation, and methods of treating inflammatory lung conditions, particularly those characterized by chronic inflammation, by administering an aerosolized anti-inflammatory macrolide compound to the lungs by inhalation. Also provided are unit dose formulations of an anti-inflammatory macrolide for aerosolized administration to the lungs by inhalation. Advantageously, the described methods and compositions allow for the targeted, localized delivery of anti-inflammatory macrolide compounds throughout the lungs without significant systemic absorption or deposition.

摘要翻译： 本文提供了药物组合物，其包含适于通过吸入对肺进行气雾化给药的抗炎大环内酯类化合物，以及通过以下方式治疗炎症性肺病症，特别是慢性炎症特征性的方法：通过向肺部施用气雾化抗炎大环内酯化合物 吸入 还提供了抗炎大环内酯的单位剂量制剂，用于通过吸入雾化给予肺部。 有利地，所描述的方法和组合物允许在整个肺部靶向，局部递送抗炎大环内酯化合物，而不会有显着的全身吸收或沉积。

公开(公告)号：US5837541A

公开(公告)日：1998-11-17

申请号：US464495

申请日：1995-06-05

申请人： Howard V. Raff

发明人： Howard V. Raff

IPC分类号： C07K14/195 ,  A61K38/00 ,  A61K39/395 ,  A61P31/04 ,  C07K14/005 ,  C07K16/00 ,  C07K16/12 ,  C07K16/14 ,  C07K19/00 ,  C12N5/00 ,  C12N5/10 ,  C12N15/00 ,  C12N15/02 ,  C12P21/00 ,  C12P21/08 ,  C12R1/91 ,  G01N33/569 ,  G01N33/577 ,  C12N5/06

CPC分类号： C07K16/1203 ,  C07K16/12 ,  A61K38/00 ,  C07K2317/77

摘要： Cell lines have been produced that secrete human monoclonal antibodies capable of binding to molecules of different bacterial species. These antibodies have been found to be protective against lethal challenges of various bacterial genera. Pharmaceutical compositions containing these antibodies, which can be in combination with other monoclonal antibodies, blood plasma fractions and antimicrobial agents, and the prophylactic and therapeutic use of such compositions in the management of infections are included. Prior to filing of this patent application the continuous transformed human cell lines 9B10, 4F10, 4B9, 7D7, and 9C3, described herein, were deposited in the American Type Culture Collection and given the designations CRL 9006, CRL 9007, CRL 9008, CRL 9009, and CRL 9239, respectively.

摘要翻译： 已经产生分泌能够结合不同细菌种类的分子的人单克隆抗体的细胞系。 已经发现这些抗体是针对各种细菌属的致死性攻击的保护。 包含可与其它单克隆抗体，血浆级分和抗微生物剂组合的这些抗体的药物组合物，以及这些组合物在感染管理中的预防和治疗用途。 在提交本专利申请之前，将本文所述的连续转化的人细胞系9B10,4F10,4B9,7D7和9C3保藏在美国典型培养物保藏中，并以CRL 9006，CRL 9007，CRL 9008，CRL 9009 ，和CRL 9239。

公开(公告)号：US5717071A

公开(公告)日：1998-02-10

申请号：US300118

申请日：1994-09-02

申请人： Howard V. Raff

发明人： Howard V. Raff

IPC分类号： C07K14/195 ,  A61K38/00 ,  A61K39/395 ,  A61P31/04 ,  C07K14/005 ,  C07K16/00 ,  C07K16/12 ,  C07K16/14 ,  C07K19/00 ,  C12N5/00 ,  C12N5/10 ,  C12N15/00 ,  C12N15/02 ,  C12P21/00 ,  C12P21/08 ,  C12R1/91 ,  G01N33/569 ,  G01N33/577 ,  C07K16/18 ,  A61K39/40 ,  C12N5/22

CPC分类号： C07K16/1203 ,  C07K16/12 ,  A61K38/00 ,  C07K2317/77

摘要： Cell lines have been produced that secrete human monoclonal antibodies capable of binding to molecules of different bacterial species. These antibodies have been found to be protective against lethal challenges of various bacterial genera. Pharmaceutical compositions containing these antibodies, which can be in combination with other monoclonal antibodies, blood plasma fractions and antimicrobial agents, and the prophylactic and therapeutic use of such compositions in the management of infections are included. Prior to filing of this patent application the continuous transformed human cell lines 9B10, 4F10, 4B9, 7D7, and 9C3, described herein, were deposited in the American Type Culture Collection and given the designations CRL 9006, CRL 9007, CRL 9008, CRL 9009, and CRL 9239, respectively.

公开(公告)号：US4970070A

公开(公告)日：1990-11-13

申请号：US189359

申请日：1988-05-02

申请人： Howard V. Raff

发明人： Howard V. Raff

IPC分类号： A61K38/00 ,  C07K16/12 ,  G01N33/569

CPC分类号： G01N33/569 ,  C07K16/12 ,  A61K38/00 ,  Y10S424/802 ,  Y10S424/803 ,  Y10S424/808 ,  Y10S435/948 ,  Y10S530/808 ,  Y10S530/809 ,  Y10S530/865

摘要： Immortalized cell lines have been produced that secrete human monoclonal antibodies capable of binding to bacterial species which are a major cause of neonatal sepsis and meningitis. These antibodies have been found to be protective against lethal challenges of these bacteria, which include group B streptococcus, E. coli, K1, and Neisseria meningitidis group B. Pharmaceutical compositions containing these antibodies, which can be in combination with other monoclonal anitbodies, blood plasma fractions and antimicrobial agents, and the prophylactic and therapeutic use of such compositions in the management of infections, are included.

摘要翻译： 已经产生了永生化的细胞系，其分泌能够结合细菌物种的人单克隆抗体，这些是新生儿败血症和脑膜炎的主要原因。 已经发现这些抗体可以防止这些细菌的致命挑战，这些细菌包括B族链球菌，大肠杆菌，K1和脑膜炎奈瑟球菌B组。含有这些抗体的药物组合物，其可以与其它单克隆抗体组合，血液 包括血浆级分和抗微生物剂，以及这些组合物在感染管理中的预防和治疗用途。